Dare Bioscience 2025 Q2 Earnings Net Loss Widens Sharply

Dare Bioscience (DARE) reported its fiscal 2025 Q2 earnings on Aug 15th, 2025. The company posted a significant net loss, marking a sharp reversal from the previous year's profit. The results fell well below expectations, with earnings per share dropping from a profit to a loss, and revenue turning negative. Despite the disappointing numbers, the CEO highlighted progress in key product development and provided forward-looking guidance.

Revenue
Dare Bioscience's total revenue declined dramatically, turning negative at $-21,172 in 2025 Q2 compared to $22,438 in 2024 Q2, representing a 194.4% decline. Royalty revenue, the sole segment reported, also fell to a negative $-21,172, reflecting a similar magnitude of decline.

Earnings/Net Income
The company swung to a loss of $0.45 per share in 2025 Q2, down from a profit of $1.53 per share in the same period the previous year—a 129.4% negative change. Dare Bioscience reported a net loss of $-4.02 million in the latest quarter, representing a 131.1% deterioration from the $12.91 million net income in 2024 Q2. The ongoing losses reflect continued financial challenges, with the company reporting negative earnings for six consecutive years in the same quarter.

Price Action
Following the earnings report, Dare Bioscience's stock experienced mixed short-term performance. Shares edged down 1.43% on the latest trading day but gained 1.47% for the week. However, the stock plunged 27.11% month-to-date, signaling continued investor pessimism.

Post-Earnings Price Action Review
The historical performance of Dare Bioscience shares following earnings reports has been poor. A strategy of buying the stock the day after the report and holding for 30 days resulted in an average return of -14.46% over the past three years, with a maximum drawdown of -32.78% during the 2023-08-14 earnings period. This suggests continued volatility and downside risk for investors holding the stock in the short term.

CEO Commentary
CEO Sabrina Martucci Johnson expressed optimism about Dare Bioscience's strategic progress in women's health. She emphasized the company is at an inflection point, with its dual-path strategy accelerating. Key upcoming milestones include the potential Q4 2025 launch of DARE to PLAY Sildenafil cream via a 503B outsourcing facility and the anticipated commercial availability of DARE-HRT1 by late 2026. Additionally, the CEO highlighted progress in the Ovaprene Phase III trial, including a positive interim DSMB review and the potential for up to $310 million in commercial milestone payments.

Guidance
Dare Bioscience expects to launch DARE to PLAY Sildenafil cream in Q4 2025 via a 503B facility, with DARE-HRT1 anticipated to follow in late 2026. The company is on track to complete the Ovaprene Phase III trial and expects to receive final data for analysis. The launch of nonprescription vaginal probiotics is slated after the Sildenafil cream launch.

Additional News
Among recent non-earnings-related news, Beijing协和医学院 announced the appointment of吉训明 as its new院校长. In the technology sector, the world's first humanoid robot sports event opened in 2025, highlighting advancements in robotics. Additionally, the Chinese government emphasized the importance of special education support, reflecting broader social policy priorities.